Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

À¯¹æ¾Ï ȯÀÚÀÇ »óÁö ºÎÀÛ¿ë°ú °ü·Ã ¿äÀÎ Arm Morbidity after Breast Cancer Treatments and Analysis of Related Factors

´ëÇѹæ»ç¼±Á¾¾çÇÐȸÁö 2005³â 23±Ç 1È£ p.32 ~ 42
¼Ò¼Ó »ó¼¼Á¤º¸
Àü¹Ì¼±/Chun MS ¹®¼º¹Ì/ÀÌÇýÁø/ÀÌÀºÇö/¼Û¿µ¼÷/Á¤¿ë½Ä/¹ÚÈñºØ/°­½ÂÈñ

Abstract

¸ñ Àû: º» ¿¬±¸ÀÇ ¸ñÀûÀº À¯¹æ¾Ï Ä¡·á ÈÄ »óÁöÀÇ ¸²ÇÁºÎÁ¾, ¾î±ú°üÀý ¿îµ¿¹üÀ§ °¨¼Ò, ÁÖ°üÀû Áõ»ó°ú ÀÌ¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â º¯¼ö¸¦ ÆľÇÇϱâ À§ÇÔÀÌ´Ù.

´ë»ó ¹× ¹æ¹ý: º» ´ëÇÐ º´¿ø¿¡¼­ À¯¹æ¾Ï Áø´ÜÀ» ¹Þ°í ¼ö¼ú ¶Ç´Â ¼ö¼ú ÈÄ ¹æ»ç¼±Ä¡·á ¹× Ç×¾ÏÄ¡·á¸¦ ¹ÞÀº ȯÀÚ 159¸íÀ» ´ë»óÀ¸·Î ¸²ÇÁºÎÁ¾ Á¤µµ¿Í ¾î±ú°üÀý ¿îµ¿¹üÀ§¸¦ ÃøÁ¤ÇÏ¿´°í, Áú¹®Áö¸¦ ÀÌ¿ëÇÏ¿© ÁÖ°üÀû Áõ»óÀ» ÃøÁ¤ÇÏ¿´´Ù. ´ë»ó ȯÀÚÀÇ 47.2%ÀÎ 75¸íÀÌ 40´ë¿´À¸¸ç 89%ÀÇ È¯ÀÚ°¡ º´±â I ¶Ç´Â II À̾ú´Ù.

°á °ú: ¸²ÇÁºÎÁ¾(°ÇÃø°ú ȯÃøÀÇ Â÷ÀÌ°¡ 2 cm ÀÌ»ó)Àº 52¸í(32.7%)ÀÇ È¯ÀÚ¿¡¼­ ¹ß»ýÇÏ¿´´Ù. ÀÌ Áß »óÁö ÇϺΠ¸²ÇÁºÎÁ¾Àº 3¸í, »óÁö »óºÎ ¸²ÇÁºÎÁ¾Àº 34¸í¿¡¼­ ¹ß»ýÇÏ¿´À¸¸ç »óÁö »óºÎ¿Í ÇϺΠ¸ðµÎ ¸²ÇÁºÎÁ¾ÀÌ ¹ß»ýÇÑ °æ¿ì´Â 15¸íÀ̾ú´Ù. °¢ ºÎÀ§º° ¹ß»ý ºóµµ´Â ¼Õ¸ñÀ¸·ÎºÎÅÍ 10 cm ÁöÁ¡¿¡¼­ 6.3%, 20 cm ÁöÁ¡¿¡¼­ 10.7%, 30 cm ÁöÁ¡¿¡¼­ 22.6%, 40 cm ÁöÁ¡¿¡¼­ 23.3%À̾ú´Ù. ¾î±ú°üÀý ¿îµ¿¹üÀ§ °¨¼Ò(°ÇÃø°ú ȯÃøÀÇ Â÷ÀÌ°¡ 20o ÀÌ»ó)ÀÇ ºóµµ´Â ±¼°î¿¡¼­ 37.2%, ¿ÜÀü¿¡¼­ 37.7%, ³»È¸Àü¿¡¼­ 48.4%, ¿ÜȸÀü¿¡¼­ 24.5%À̾ú´Ù. ÀÌ Áß ³»È¸ÀüÀÇ °æ¿ì Á¤»ó¿îµ¿¹üÀ§ÀÇ 50% ÀÌ»ó °¨¼ÒµÇ´Â °æ¿ìµµ ÈçÇÏ¿´´Ù. ÁÖ°üÀû Áõ»óÀ¸·Î ÅëÁõ È£¼Ò°¡ 63.5%, ÆÈÀ» ¿òÁ÷À̱â Èûµé´Ù°í ÇÏ´Â °æ¿ì°¡ 48.4%, ÆÈÀú¸² È£¼Ò°¡ 69.8%, »»»»ÇÔ(stiffness) È£¼Ò°¡ 69.2%À̾ú´Ù. ƯÈ÷ ¸²ÇÁºÎÁ¾ÀÌ ¾ø´Â 108¸íÀÇ È¯ÀÚ Áß 66¸í(61.1%)ÀÌ ÅëÁõÀ» È£¼ÒÇÏ¿´´Ù. ¸²ÇÁºÎÁ¾ÀÇ ¹ß»ý°ú À¯ÀÇÇÑ °ü°è°¡ ÀÖ´Â ¿äÀÎÀ¸·Î´Â ¿¬·É, üÁú·®Áö¼ö(BMI), Ä¡·á¹æ¹ý ¹× ¼ö¼ú ÈÄ °æ°ú±â°£ÀÌ ÀÖ¾ú°í, ¾î±ú°üÀý ¿îµ¿¹üÀ§ °¨¼ÒÀÇ °æ¿ì Ä¡·á¹æ¹ý°ú ¼ö¼ú ÈÄ °æ°ú±â°£À̾ú´Ù. ÁÖ°üÀû Áõ»óÀÇ °æ¿ì´Â Ä¡·á¹æ¹ý°ú ¼ö¼ú ÈÄ °æ°ú±â°£ ±×¸®°í Ç×¾ÏÈ­Çпä¹ý Á¾·ù°¡ À¯ÀÇÇÑ °ü°è°¡ ÀÖ´Â ¿äÀÎÀ̾ú´Ù. ´Ùº¯·®ºÐ¼® °á°ú üÁú·®Áö¼ö(BMI)¿Í ¼ö¼ú ÈÄ °æ°ú±â°£ÀÌ ¸²ÇÁºÎÁ¾¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â À¯ÀÇÇÑ º¯¼öÀÎ °ÍÀ¸·Î ³ªÅ¸³µ´Ù.

°á ·Ð: ¸²ÇÁºÎÁ¾Àº ¼ö¼ú ÈÄ ±â°£ÀÌ °æ°úµÇ¾îµµ °è¼Ó ÁøÇàµÇ¸ç ƯÈ÷ üÁú·®Áö¼ö°¡ À¯ÀÇÇÑ ¿äÀÎÀ¸·Î È®ÀεǾî Áö¼ÓÀûÀΠüÁß°ü¸®¸¦ Æ÷ÇÔÇÑ ¿¹¹æ´ëÃ¥ÀÌ ÇÊ¿äÇÏ´Ù. ±×¸®°í ¾î±ú°üÀý ¿îµ¿¹üÀ§ÀÇ °¨¼Òµµ ȯÀÚÀÇ ¾à 1/3¿¡¼­ ¹ß»ýÇÏ¿´À¸¸ç ƯÈ÷ ±¼°î, ¿ÜÀü, ³»È¸Àü ¿îµ¿¹üÀ§ÀÇ °¨¼Ò°¡ ºó¹øÇÏ¿´°í ³»È¸ÀüÀÇ °æ¿ì ±× Á¤µµ°¡ ½ÉÇÏ¿´À¸¸ç À̸¦ ±Ù°Å·Î ÇÑ Ä¡·á ÈÄ ÀçÈ°°ü¸® ÇÁ·Î±×·¥ÀÌ È¯ÀÚ¿¡°Ô µµ¿òÀ» ÁÙ °ÍÀ¸·Î ±â´ëÇÑ´Ù.


Purpose: To evaluate the incidence of arm morbidity following breast cancer surgery including axillary dissection and to identify related factors.

Materials and Methods: One hundred and fifty nine patients were studied using a self-report questionnaire and a clinical examination. Lymphedema, reduction of range of motion in shoulder joint and subjective symptoms (pain, impaired arm movement, numbness, stiffness) were evaluated. As related factors, demographic, oncologic characteristics and types of treatment were analysed.

Results: The incidence of lymphedema (¡Ã2 cm difference comparing to unaffected arm) was 6.3%, 10.7%, 22.6% and 23.3% at each 10 cm, 20 cm, 30 cm, and 40 cm from wrist. Reduction of range of motion in shoulder joint (¡Ã20 degree difference comparing to unaffected arm) was noted in more than 1/3 patients for flexion, abduction and internal rotation. Especially the reduction of range of motion in internal rotation was severe (£¾50% reduction) in 1/3 patients. Approximately 50 to 60% of patients complained impaired arm movement, numbness, stiffness and pain. Body mass index (BMI) was the significant risk factor for lymphedema.

Conclusion: Lymphedema was present in 1/3 of patients and the common sites of edema were 30 cm 40 cm proximal from the wrist. Also most severe reduction of range of motion in shoulder joint was with internal rotation. There needs weight control for lymphedema because BMI was the significant risk factor for lymphedema. Also rehabilitation program for range of motion especially internal rotation in shoulder joint should be developed.

Å°¿öµå

Arm morbidity; Axillary dissection; Breast cancer; À¯¹æ¾Ï; ¸²ÇÁºÎÁ¾; ¾î±ú°üÀý ¿îµ¿¹üÀ§; ÁÖ°üÀû Áõ»ó

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS